Rentschler
Rentschler Biopharma SE, commonly referred to as Rentschler, is a leading contract development and manufacturing organisation (CDMO) headquartered in Laupheim, Germany. Established in 1921, Rentschler has built a strong reputation in the biopharmaceutical industry, specialising in the development and production of complex biopharmaceuticals, including monoclonal antibodies and recombinant proteins. With a commitment to quality and innovation, Rentschler offers a comprehensive range of services, from cell line development to commercial manufacturing. The company is recognised for its unique approach to tailored solutions, ensuring that clients receive personalised support throughout the product lifecycle. Rentschler's strategic focus on quality and regulatory compliance has positioned it as a trusted partner for biopharmaceutical companies worldwide, contributing to its notable achievements in the sector.
DitchCarbon Score
How does Rentschler's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Rentschler's score of 3 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Rentschler's reported carbon emissions
Rentschler Biopharma SE, headquartered in Germany, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established near-term targets to reduce absolute Scope 1 and Scope 2 emissions by approximately 37.8% by the fiscal year 2029, using the fiscal year 2023 as a baseline. In addition to its direct emissions reduction goals, Rentschler Biopharma is committed to ensuring that about 81.8% of its suppliers, based on emissions from purchased goods and services, will have science-based targets in place by FY2029. This commitment aligns with industry standards for climate action and reflects the company's dedication to sustainable practices within its supply chain. Rentschler Biopharma's targets are consistent with the reductions necessary to limit global warming to 1.5°C, demonstrating its commitment to addressing climate change effectively. While the company has not yet committed to a net-zero target, its proactive approach to emissions reduction positions it as a responsible player in the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Rentschler is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
